News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tanox, Inc. (TNOX) Initiates Phase 1 Clinical Trial Evaluating TNX-650 For Treatment Of Asthma



10/25/2006 12:25:16 PM

HOUSTON, Oct. 25 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX - News) has begun dosing a Phase 1 clinical trial of TNX-650, a humanized monoclonal antibody being evaluated as a potential treatment for moderate-to-severe asthma.

Read at press release


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES